Company: SHPH
Filing Date: 2025-10-21
Form Type: 8-K
Source: 0001493152-25-018788
Chunk: 1

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-10-21
Form: 8-K
Item: Item 1.02
Chunk 1
---
Item
1.02 Termination of a Material Definitive Agreement.

On
October 15, 2025, the Company received a letter from Theradex Systems, Inc. (“ Theradex”), providing written notice of termination
of the master agreement, dated November 1, 2018 (the “ Master Agreement”), between Shuttle Pharmaceuticals, Inc. (the Company’s
wholly-owned subsidiary) (“ Shuttle”) and Theradex, and all work orders thereunder, and demanding immediate payment of all
outstanding amounts owed thereunder in the aggregate amount of $1.091 million. Theradex is the Company’s primary third-party contract
research organization (or CRO).

Pursuant
to the Master Agreement, Shuttle engaged Theradex to provide certain regulatory and clinical research services (the “ Services”),
as further detailed in work orders thereunder. Theradex provided notice of its intent to terminate the Master Agreement pursuant to a
provision thereunder permitting either party to terminate the Master Agreement upon the material breach of the other party, which breach
continues for 30 days after delivery to the breaching party of notice of such material breach. Theradex states in the letter that if
Shuttle fails to pay the outstanding amounts within 30 days of the date of the letter, Theradex will cease providing the Services under
the Master Agreement.

Item
9.01 Financial Statements and Exhibits.